Atossa Therapeutics (ATOS) Stock Sees Huge Jump: Will It Hit $10?

The Atossa Therapeutics (NASDAQ:ATOS) stock has been one of the biggest movers in...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more

trending

Here's Who Just Picked Up Dynatronics Corp (NASDAQ:D...
Inspira Technologies IINN is Up, Why is That? Take a...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Announ...

The Atossa Therapeutics (NASDAQ:ATOS) stock has been one of the biggest movers in the market over the course of the past months and the rally continued in the stock on Tuesday.

Yesterday, the stock came into sharp focus among investors and managed to record gains of 51% for the week so far. More importantly, the rally took the gains recorded by the Atossa stock over the course of the past six months to as much as 680%. Considering the magnitude of the gains made by the stock this week, it might be a good idea to take a look at the major factors that were at play.

One of the more important milestones achieved by the company in recent times is that of being included in the Russell 3000 and Russell 2000 indexes. That might have been one of the factors why fund managers might have been acquiring the Atossa stock. However, that is not the only factor at play.

There is another group of investors, including those from the Reddit community, who are attempting to trigger a gamma squeeze in the Atossa stock. These traders have been picking up plenty of short-dated call options in the Atossa stock with the aim of forcing market makers to buy more of these shares.

If that happens then the price of the Atossa stock is going to go higher. While these may be some of the factors behind the latest rally, it should be noted by investors that these factors can only bring about a temporary rise in the stock price.

The long-term fate of the stock is going to be dependent on the company’s business. At this point in time, the company has two products in its pipeline. Not too long ago, Atossa had published the Phase 2 results in relation to its breast cancer medicine Endoxifen.

Stay in the lopp :

Parker Drilling Co (NYSE:PKD) is Attracting S...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Parker Drilling Co (NYSE:PKD) reported that Brigade Capital has picked
Biofrontera Inc. (Nasdaq: BFRI Patent allowed!

Company Name: Biofrontera Inc. 

Ticker: (BFRI)

Exchange: NASDAQ

Website: www.biofrontera-us.com

<!-- wp:paragraph
Guess Who Picked Audentes Therapeutics Inc. (...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Audentes Therapeutics Inc. (NASDAQ:BOLD) reported that Flynn James E  has

related post

Skip to content